Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study

Απλή σελίδα τεκμηρίου
dc.contributor.authorAthyros, V. G.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorLiberopoulos, E. N.en
dc.contributor.authorKakafika, A. I.en
dc.contributor.authorKaragiannis, A.en
dc.contributor.authorPapageorgiou, A. A.en
dc.contributor.authorTziomalos, K.en
dc.contributor.authorGanotakis, E. S.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T19:22:29Z
dc.date.available2015-11-24T19:22:29Z
dc.identifier.issn0931-0509-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22167
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectCoronary Disease/ blood/drug therapyen
dc.subjectCost-Benefit Analysisen
dc.subjectCreatinine/blooden
dc.subjectFemaleen
dc.subjectGlomerular Filtration Rateen
dc.subjectGreeceen
dc.subjectHeptanoic Acids/therapeutic useen
dc.subjectHumansen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/ therapeutic useen
dc.subjectKidney/ drug effectsen
dc.subjectMaleen
dc.subjectMetabolic Syndrome X/ blooden
dc.subjectMiddle Ageden
dc.subjectPyrroles/therapeutic useen
dc.subjectUric Acid/ blooden
dc.titleEffect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Studyen
heal.abstractBACKGROUND: Metabolic syndrome (MetS) is associated with increased risk for both vascular and chronic kidney disease. Whether statins ameliorate these risks is not established. METHODS: This post hoc analysis of the GREek Atorvastatin and Coronary heart disease (CHD). Evaluation (GREACE) examines the effect of statins on estimated glomerular filtration rate (e-GFR) and serum uric acid (SUA) levels and their relation to vascular events in CHD patients with MetS. MetS patients were divided into two groups: Group A (n = 365) received lifestyle advice, target-driven treatment with statins (mainly atorvastatin) and treatment for hypertension and elevated glucose. Group B (n = 347) received the same except for statins. Patients without MetS were divided into those who received treatment similar to Group A and Group B [Groups C (n = 504) and D (n = 384), respectively]. All patients were followed for 3 years. RESULTS: A total of 12.1% of patients in Group A experienced a vascular event vs 28% in Group B; risk ratio (RR) 0.43, 95% confidence interval (CI) 0.20-0.64, P < 0.0001, while in those without MetS (Group C vs Group D), the respective RR was 0.59, 95% CI 0.41-0.79, P < 0.0001. In Group A, e-GFR increased by 13.7% and SUA levels fell by 8.9%, while in Group B e-GFR was reduced by 5.8% and SUA increased by 4.3% (P < 0.005). Stepwise regression analysis showed that these changes were independently related to vascular events. CONCLUSION: Among CHD patients, those with MetS benefited more from statin treatment than those without MetS. This benefit could be partially attributed to favourable changes in e-GFR and SUA levels probably induced by statin treatment.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1093/ndt/gfl538-
heal.identifier.secondaryhttp://ndt.oxfordjournals.org/content/22/1/118.full.pdf-
heal.journalNameNephrol Dial Transplanten
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2007-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ